Hodgkin lymphoma pathogenesis linked to inflammation caused by Epstein-Barr virus

06-08-2006

Hodgkin lymphoma (HL) pathogenesis could be linked to chronic inflammation caused by Epstein-Barr virus (EBV).

According to recent research from England, "The association between chronic inflammation and cancer has been known for well over a century. However, direct evidence detailing the role of inflammation in carcinogenesis has been slow in forthcoming."

"A number of recent studies suggest that the gaps in our understanding of the molecular pathways bridging the link between inflammation and cancer are slowly beginning to close and that this relationship is more deep-rooted than had been previously believed," explained G. Khan and colleagues, Kingston University. "This review addresses the link between inflammation and HL, a malignancy which has many features reminiscent of chronic inflammation.

"The role of EBV in the pathogenesis of HL is discussed, along with an outline of our current understanding of the cellular nature and development of Reed-Sternberg cells, the malignant cells of HL. The involvement of cytokines and chemokines as orchestrators of inflammation and vehicles for chemical cross-talk between the malignant cells and the reactive inflammatory infiltrate forms a major part of the review."

The researchers concluded, "It is suggested that chronic inflammation, triggered by factors such as EBV, is likely to contribute to tumor cell proliferation, progression, and inhibition of apoptosis. Furthermore, it is proposed that the pro-inflammatory transcription factor NF-kappa B plays a central role in many of these processes."

Khan and colleagues published their study in Experimental Hematology (Epstein-Barr virus, cytokines, and inflammation: A cocktail. for the pathogenesis of Hodgkin's lymphoma? Exp Hematol, 2006;34(4):399-406).

For additional information, contact G. Khan, Kingston University, School Life Science, Kingston upon Thames KT1 2EE, Surrey, England.

Publisher contact information for the journal Experimental Hematology is: Elsevier Science Inc., 360 Park Avenue South, New York, NY 10010-1710, USA.

Keywords: Kingston upon Thames, County: Surrey, England, Apoptosis, Carcinogenesis, Chronic Fatigue Syndrome, EBV, Epstein-Barr Virus, Hematology, Herpes, Herpesvirus, Lymphoma, Oncology, Pathogenesis, Virology, Chronic Inflammation.

This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2006, Clinical Oncology Week via NewsRx.com.



Related Diseases: Hodgkin Lymphoma
Related Keywords: Apoptosis
 
RECENT NEWS
 
Acute Lymphocytic Leukemia (ALL)
2008 SF Leukemia Cup Regatta - Sailing for Leukemia
CombiMatrix Announces That Permission Has Been Granted to Begin Clinical Trial for Leuchemix Drug
Improved Survival in Pediatric Leukemia Following Unrelated Bone Marrow but not Peripheral Blood Stem Cell Transplantation
Hana Biosciences' rALLy Clinical Trial of Marqibo Meets Response Criteria to Advance to Full Enrollment
Rituxan® Maintenance in Follicular Lymphoma Deemed Cost-effective
Acute Myeloid Leukemia (AML)
2008 SF Leukemia Cup Regatta - Sailing for Leukemia
CombiMatrix Announces That Permission Has Been Granted to Begin Clinical Trial for Leuchemix Drug
Improved Survival in Pediatric Leukemia Following Unrelated Bone Marrow but not Peripheral Blood Stem Cell Transplantation
New leukemia signal could point way to better treatment, Stanford researchers find
Cyclacel expands Phase 2 sapacitabine trial in elderly AML to include patients with MDS
Amyloidosis
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
STEM CELL TRANSPLANTATION PROCEDURE RESULTS IN LONG-TERM SURVIVAL FOR AMYLOIDOSIS PATIENTS
Neurochem receives approvable letter for eprodisate (KIACTA) for treatment of AA amyloidosis
Neurochem, Inc. (NRMX) Receives Approvable Letter for Eprodisate (KIACTA(TM)) for Treatment of AA Amyloidosis; FDA Asks for More Data
Aplastic Anemia
Blood Stem Cells Originate in the Placenta
Stem Cells from a Person's Own Umbilical Cord Effective Treatment For Life-Threatening Blood Disease, Study Data Show
Alexion's Soliris Granted Marketing Approval in Europe for Treatment of All Patients With PNH
Soliris(TM) Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
Decision Fails Patients with Transfusion-Dependent Anemia
Chronic Lymphocytic Leukemia (CLL)
Phase III Study of Rituxan in Leukemia Meets its Goal
2008 SF Leukemia Cup Regatta - Sailing for Leukemia
CombiMatrix Announces That Permission Has Been Granted to Begin Clinical Trial for Leuchemix Drug
Improved Survival in Pediatric Leukemia Following Unrelated Bone Marrow but not Peripheral Blood Stem Cell Transplantation
Injection of Umbilical Cord Stem Cells into Bone Appears Promising for Leukemia
Chronic Myeloid Leukemia (CML)
2008 SF Leukemia Cup Regatta - Sailing for Leukemia
CombiMatrix Announces That Permission Has Been Granted to Begin Clinical Trial for Leuchemix Drug
Improved Survival in Pediatric Leukemia Following Unrelated Bone Marrow but not Peripheral Blood Stem Cell Transplantation
Promyelocytic Blast Crisis of Chronic Myeloid Leukemia during Imatinib Treatment
Injection of Umbilical Cord Stem Cells into Bone Appears Promising for Leukemia
Hodgkin Lymphoma
Hodgkin lymphoma -- new characteristics discovered
Queen's University Using Xceed Molecular's Ziplex in Follicular Lymphoma Study
Lymphoma 101: Everything you need to know
September Is National Leukemia and Lymphoma Awareness Month
Nerve cancer mutations found
Multiple Myeloma
Thalomid® in Induction Improves Progression-free Survival in Elderly with Myeloma
The IMF says journal editorial documents dramatic increase in survival since the 1980s
FDA Approves Vidaza Label Expansion
Bortezomib (Velcade) in Combo Scores For Initial Myeloma Treatment
B-MS boosts biologics pipeline with PDL BioPharma deal
Myelodysplastic Syndrome (MDS)
Cyclacel expands Phase 2 sapacitabine trial in elderly AML to include patients with MDS
FDA Approves Vidaza Label Expansion
Xanthus Presents Updated Xanafide Phase 2 Data Showing Durable Complete Remissions in Secondary AML
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine (VNP40101M) in Combination with Cytarabine
ZIOPHARM Presents Positive Data From Phase II Study Of Darinaparsin In Advanced Hematological Malignancies At AACR 2008 Annual Meeting
Non-Hodgkin Lymphoma (NHL)
Queen's University Using Xceed Molecular's Ziplex in Follicular Lymphoma Study
Lymphoma 101: Everything you need to know
Dose Intensity Associated with Survival in Non-Hodgkin’s Lymphoma
September Is National Leukemia and Lymphoma Awareness Month
Dose Intensity Associated with Survival in Non-Hodgkin’s Lymphoma
Testicular Cancer
Single Dose of Carboplatin as Effective as Radiation Therapy for Testicular Cancer
Single Dose of Chemotherapy as Effective as Weeks of Radiation Therapy for Testicular Cancer
Drug avoids radiation for early testicular cancer
Polymorphism Reduces Benefit of Bleomycin in Testicular Cancer
Increased Life Expectancy Seen For Patients With Advanced Colorectal, Ovarian and Testicular Cancer